News – Alligator Bioscience

2026-04-20

New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026

Lund, Sweden – 20 April 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...

2026-04-10

Lund, Sweden – 10 April 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...

2026-03-31

Regulatory

During March 2026, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a result ...

2026-03-30

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2026-03-27

Regulatory

The Nomination Committee of Alligator Bioscience AB (publ) (“Alligator Bioscience”) proposes re-election of Hans-Peter Ostler an ...

2026-03-26

Regulatory

Lund, Sweden, 26 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2025, as well ...

2026-03-20

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2026-03-18

Lund, Sweden – 18 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...

2026-03-16

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...